TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12100090

Group type: EXPERIMENTAL
Intervention: 1 mg butorphanol administered 1 min after sumatriptan
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1 mg butorphanol administered 30 min after sumatriptan
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 20 mg sumatriptan
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of sumatriptan and butorphanol
Number of subjects: 24
Study: 10442961

Group type: EXPERIMENTAL
Intervention: Targeted injections of 5 ml mepivacaine 1% with epinephrine (MEPE)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Single injection of 80 mL MEPE 1%
Number of subjects: 106
Study: 8551821

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 129

Group type: COMPARATOR
Intervention: Intravenous glyceryl trinitrate
Number of subjects: 129
Study: 2191595

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg qid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (ranitidine-matched) bid
Number of subjects: 12
Study: 68285

Group type: EXPERIMENTAL
Intervention: Mass-media campaigns over a 2-year period in two communities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face-to-face counselling for a small subset of high-risk people
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control community (no intervention)
Number of subjects: 0
Study: 31782931

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Strength Training with Blood Flow Restriction (ST-BFR)
Number of subjects: 30
Study: 30923776

Group type: EXPERIMENTAL
Intervention: Social skills training intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 50
Study: 28702807

Group type: EXPERIMENTAL
Intervention: Rest-pause training (4-s unloaded rest between repetitions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (Rest-pause and Traditional)
Number of subjects: 20
Study: 25560820

Group type: EXPERIMENTAL
Intervention: 250 mg/day of olive extract and 1000 mg Ca
Number of subjects: 64

Group type: COMPARATOR
Intervention: 1000 mg Ca alone (placebo)
Number of subjects: 64
Study: 23871127

Group type: EXPERIMENTAL
Intervention: Combined Psychotherapy and Illness Management
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Illness Management Only
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 83
Study: 21336438

Group type: EXPERIMENTAL
Intervention: Perioperative immune-enhancing formula (DS group)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional postoperative intravenous fluids (DNS group)
Number of subjects: 82
Study: 17978833

Group type: EXPERIMENTAL
Intervention: Contrast water therapy (CWT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cold water immersion (CWI)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hot water immersion (HWI)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Passive recovery (PAS)
Number of subjects: 38
Study: 15702819

Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (250/50 microg twice daily)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Fluticasone (250 microg twice daily)
Number of subjects: 192
Study: 12934861

Group type: EXPERIMENTAL
Intervention: Integrated case management (ICM) approach with problem solving skills training and workplace accommodation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (case managers who did not receive training)
Number of subjects: 70
Study: 10376232

Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of three sessions on AHCPR depression guidelines and case-finding instrument for depression
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (non-intervention residents)
Number of subjects: 160
Study: 8762735

Group type: EXPERIMENTAL
Intervention: 0.1 microgram/min GnRH
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.25 microgram/min GnRH
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.5 microgram/min GnRH
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1.0 microgram/min GnRH
Number of subjects: 24
Study: 1757390

Group type: EXPERIMENTAL
Intervention: 50% VO2max
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 60% VO2max
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 70% VO2max
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 80% VO2max
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 90% VO2max
Number of subjects: 6
Study: 7201838

Group type: EXPERIMENTAL
Intervention: Cosaldon (1-hexyl-3,7-dimethylxanthine + nicotinic acid)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29470249

Group type: EXPERIMENTAL
Intervention: elevated serum uric acid (eSUA)
Number of subjects: 101

Group type: COMPARATOR
Intervention: non-elevated serum uric acid (non-eSUA)
Number of subjects: 101
Study: 27521806

Group type: EXPERIMENTAL
Intervention: On the Move group exercise program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard group exercise program
Number of subjects: 0
Study: 24107360

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 3690
Study: 22100357

Group type: EXPERIMENTAL
Intervention: Tropisetron 2mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tropisetron 5mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tropisetron (both doses)
Number of subjects: 30
Study: 20690560

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a with ribavirin
Number of subjects: 443

Group type: COMPARATOR
Intervention: Interferon alfa-2a with ribavirin
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Number of subjects: 443

Group type: COMPARATOR
Intervention: Interferon alfa-2a
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Slow response (detectable HCV RNA at week 12 and undetectable at week 24)
Number of subjects: 443
Study: 18387159

Group type: EXPERIMENTAL
Intervention: Cinacalcet 12.5 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cinacalcet 25 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cinacalcet 50 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 16311279

Group type: EXPERIMENTAL
Intervention: Saline
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Gelatin 4%
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: HES 6%
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Albumin 5%
Number of subjects: 67
Study: 12904966

Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 11035971

Group type: EXPERIMENTAL
Intervention: Type III collagen deficiency in AAA patients
Number of subjects: 138

Group type: COMPARATOR
Intervention: Normal type III collagen in family members
Number of subjects: 138

Group type: COMPARATOR
Intervention: Screening for AAA in relatives
Number of subjects: 138
Study: 8673778

Group type: EXPERIMENTAL
Intervention: Buffered 1% lidocaine
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Buffered 1% lidocaine with epinephrine
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Plain 1% lidocaine with epinephrine
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.5% diphenhydramine with epinephrine
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine with epinephrine
Number of subjects: 180
Study: 1666460

Group type: EXPERIMENTAL
Intervention: Logiparin
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 456
Study: 6145734

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam with a narcotic
Number of subjects: 0
Study: 31250832

Group type: EXPERIMENTAL
Intervention: Depressive users dataset
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control dataset
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Depressive users and depressive tweets datasets
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Depressive tweets dataset
Number of subjects: 540
Study: 28954218

Group type: EXPERIMENTAL
Intervention: Insulin therapy (Detemir, Aspart, and their combination) as an add-on to metformin for 4 weeks
Number of subjects: 42
Study: 26818362

Group type: EXPERIMENTAL
Intervention: Individualised information and emotional support (30 minutes) provided one day before surgery
Number of subjects: 253

Group type: COMPARATOR
Intervention: Routine information as usual (control group)
Number of subjects: 253
Study: 24602411

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system (up to 16 mg/24 h)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 22724619

Group type: EXPERIMENTAL
Intervention: Family interventions (n=459)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Control group (n=208)
Number of subjects: 667
Study: 20043182

Group type: EXPERIMENTAL
Intervention: Nailfold capillaroscopy (NFC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Plasma endothelin-1 (ET-1) measurement
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nailfold capillaroscopy (NFC) and plasma ET-1 correlation
Number of subjects: 60
Study: 17437832

Group type: EXPERIMENTAL
Intervention: Visualization of the video screen during cystoscopy (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No visualization of the video screen during cystoscopy (Group 2)
Number of subjects: 100
Study: 16415516

Group type: EXPERIMENTAL
Intervention: Bicarbonated Ringer's solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acetated Ringer's solution
Number of subjects: 20
Study: 12578513

Group type: EXPERIMENTAL
Intervention: Onsite feedback presentations, performance improvement materials, comparative measures of performance of predefined quality indicators (intervention group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (16 hospitals)
Number of subjects: 36
Study: 10385715

Group type: EXPERIMENTAL
Intervention: Rigid dilator (Savary)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Balloon dilator (Microvasive)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Balloon dilator (Bard)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Moderate/severe strictures
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: All groups (Rigid and Balloon)
Number of subjects: 251
Study: 8734709

Group type: EXPERIMENTAL
Intervention: Penicillin VK group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Neither medication group
Number of subjects: 32
Study: 2021446

Group type: EXPERIMENTAL
Intervention: Metoprolol (n = 1,609)
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Thiazide diuretic (n = 1,625)
Number of subjects: 3234
Study: 7138230

Group type: EXPERIMENTAL
Intervention: Therapeutic community ward
Number of subjects: 123

Group type: COMPARATOR
Intervention: Medically oriented psychiatric ward
Number of subjects: 123
Study: 30452739

Group type: EXPERIMENTAL
Intervention: Nicotine patch and behavioral counseling
Number of subjects: 525
Study: 30153360

Group type: EXPERIMENTAL
Intervention: Active bifrontal tDCS with concurrent CBT
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham bifrontal tDCS with concurrent CBT
Number of subjects: 14
Study: 30375894

Group type: EXPERIMENTAL
Intervention: Aerobic exercise at 60% of peak oxygen consumption
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Aerobic exercise at 90% of peak oxygen consumption
Number of subjects: 27

Group type: COMPARATOR
Intervention: Comparison of moderate and severe COPD groups
Number of subjects: 27
Study: 26549819

Group type: EXPERIMENTAL
Intervention: ROLL
Number of subjects: 129

Group type: COMPARATOR
Intervention: WGLL
Number of subjects: 129
Study: 25016922

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC), 3 cycles of lower limb ischemic conditioning before allograft reperfusion.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no RIC).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC).
Number of subjects: 60
Study: 21106282

Group type: EXPERIMENTAL
Intervention: liposome‐encapsulated 2% ropivacaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: liposome‐encapsulated 1% ropivacaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Eutectic mixture of 2.5% lidocaine and 2.5% prilocaine (EMLA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: liposomal placebo gel
Number of subjects: 40
Study: 19843060

Group type: COMPARATOR
Intervention: Clozapine (CLZ) alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clozapine-Risperidone (CLZ-RISP) combination
Number of subjects: 20
Study: 17495570

Group type: EXPERIMENTAL
Intervention: Personal DXA information (experimental group)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (no personal DXA information)
Number of subjects: 203
Study: 15973213

Group type: EXPERIMENTAL
Intervention: Minimally invasive radioguided parathyroidectomy (MIRP)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Bilateral exploration of the neck
Number of subjects: 69
Study: 11940299

Group type: EXPERIMENTAL
Intervention: Exercise during hemodialysis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 20
Study: 9775742

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study: 7716838

Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin, bacille Calmette‐Guérin (BCG)‐RIVM or BCG‐Tice
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nonresponding patients
Number of subjects: 52
Study: 2496989

Group type: EXPERIMENTAL
Intervention: Booster injection of 0.1, 0.25 or 0.5 ml of diphtheria-tetanus vaccine
Number of subjects: 457

Group type: COMPARATOR
Intervention: Diphtheria-tetanus primary vaccinations over wider intervals
Number of subjects: 457
Study: 197502

Group type: EXPERIMENTAL
Intervention: Nursing services (treatment group)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no nursing services)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study: 31792947

Group type: EXPERIMENTAL
Intervention: Intervention group (GP-led deprescribing intervention)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 145
Study: 30225662

Group type: EXPERIMENTAL
Intervention: Evidence-Based Practices (EBP) for children with autism spectrum disorder
Number of subjects: 46
Study: 28777729

Group type: EXPERIMENTAL
Intervention: Constrained empirical risk minimization framework of CCA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kernel version of CCA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-stage randomized Kaczmarz method
Number of subjects: 0
Study: 26407829

Group type: EXPERIMENTAL
Intervention: Flexion group (affected leg elevated by 60° at the hip and knee flexed by 60°)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Extension group (affected knee fully extended postoperatively)
Number of subjects: 46
Study: 23642981

Group type: EXPERIMENTAL
Intervention: Brief psychodynamic therapy (24 subjects)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Medical treatment alone (25 subjects)
Number of subjects: 49
Study: 21871080

Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Footwear advice and footwear cost subsidy
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Home‐based foot and ankle exercise program
Number of subjects: 153
Study: 19863217

Group type: EXPERIMENTAL
Intervention: No activity restrictions (NAR) combined with a moderate resistance exercise program
Number of subjects: 204

Group type: COMPARATOR
Intervention: Activity restrictions (AR) combined with a usual care program
Number of subjects: 204
Study: 16910360

Group type: EXPERIMENTAL
Intervention: Lichtenstein mesh
Number of subjects: 70

Group type: COMPARATOR
Intervention: Rutkow-Robbins plug and mesh
Number of subjects: 70
Study: 15575902

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 214

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 214
Study: 11759858

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix allograft
Number of subjects: 9

Group type: COMPARATOR
Intervention: Connective tissue graft with coronally positioned flap
Number of subjects: 9
Study: 9387963

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation assessment using rapid airway occlusion technique
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Computed tomography scans
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Assessment of interrupter resistance (Rint)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Static inflation volume-pressure (V-P) curve assessment
Number of subjects: 12
Study: 7663467

Group type: EXPERIMENTAL
Intervention: Quality 1 bone
Number of subjects: 2131

Group type: EXPERIMENTAL
Intervention: Quality 2 bone
Number of subjects: 2131

Group type: EXPERIMENTAL
Intervention: Quality 3 bone
Number of subjects: 2131
Study: 3111179

Group type: EXPERIMENTAL
Intervention: Novel aldose reductase inhibitor (ARI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (patients without AN)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ARI treatment
Number of subjects: 30
Study: 31531997

Group type: EXPERIMENTAL
Intervention: Immunonutrition supplements (3 supplements/day for 5 days)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard polymeric supplements (3 supplements/day for 5 days)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Immunonutrition and Standard polymeric supplements
Number of subjects: 108
Study: 30848558

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) plus nonbiologic background medication (NBBM)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo plus nonbiologic background medication (NBBM)
Number of subjects: 317
Study: 26803169

Group type: EXPERIMENTAL
Intervention: SeY-100/d (100 μg Se/day)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: SeY-50/d (50 μg Se/day)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: SeY-200/d (200 μg Se/day)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: SeO-50/d (50 μg Se/day)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Onion (control)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Se supplementation (various doses)
Number of subjects: 117
Study: 25518754

Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP) and Samidorphan (SAM) in a 1:1 ratio for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23223915

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 50
Study: 21519309

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (1 mg/kg per hour) with patient-controlled analgesia morphine for the first 48 hours after surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia with patient-controlled analgesia morphine for the first 48 hours after surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (TEA and IL)
Number of subjects: 60
Study: 18211939

Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 65

Group type: COMPARATOR
Intervention: 0.5% levobupivacaine/2% lidocaine mixture
Number of subjects: 65
Study: 17062741

Group type: EXPERIMENTAL
Intervention: 1.25 mM CuSO4
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Amine fluoride (250 ppm F)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Copper and amine fluoride combined
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 14
Study: 15536784

Group type: EXPERIMENTAL
Intervention: Minocycline microspheres
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chlorhexidine gel
Number of subjects: 30
Study: 10903240

Group type: EXPERIMENTAL
Intervention: montelukast at 5 mg/d for 2 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: montelukast
Number of subjects: 13
Study: 9305235

Group type: EXPERIMENTAL
Intervention: Mixed weed extract (1:2500 wt/vol to 1:10 wt/vol) administered daily for 12 to 16 weeks with 5.2 mg intranasal cromolyn pretreatment.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 27
Study: 8454221

Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral hydralazine
Number of subjects: 0
Study: 3096592

Group type: EXPERIMENTAL
Intervention: Terfenadine suspension, 30 mg b.i.d.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 29800001

Group type: EXPERIMENTAL
Intervention: CPAP users (72 participants, mean use 6.4 hours per night)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: CPAP users (72 participants)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: CPAP users (women subgroup)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: CPAP users (men subgroup)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Nonusers (110 participants, mean use 0 hours per night)
Number of subjects: 182
Study: 26848545

Group type: EXPERIMENTAL
Intervention: 80% 1 repetition maximum (1RM) resistance training
Number of subjects: 15

Group type: COMPARATOR
Intervention: 30% 1 repetition maximum (1RM) resistance training
Number of subjects: 15
Study: 25054430

Group type: EXPERIMENTAL
Intervention: Dofetilide (pure hERG potassium channel blocker)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Quinidine (blocks hERG and calcium currents)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ranolazine (blocks hERG and late sodium currents)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Verapamil (blocks hERG and calcium currents)
Number of subjects: 22
Study: 22209475

Group type: EXPERIMENTAL
Intervention: Electromechanical device systems (2 types), 5 days per week for 8 weeks
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Electromechanical systems
Number of subjects: 130